Erschienen in:
03.05.2018 | Letter
Reply to “At what price decreased mortality risk?”
verfasst von:
K.L. Ong, D.P. Beall, M. Frohbergh, E. Lau, J.A. Hirsch
Erschienen in:
Osteoporosis International
|
Ausgabe 8/2018
Einloggen, um Zugang zu erhalten
Excerpt
Rodriguez and Ebeling provide thoughtful comments regarding our study [
1]. They agreed with the well-documented fact that fewer augmentations were done following publication of the 2009 “sham” trials [
2]. Moreover, they acknowledged the resultant elevated mortality risk in VCF patients from 2010 to 2014. We agree with their statement that it is “alarming though that the reductions in mortality risks in the post-2009 (sham trials) era were attenuated.” …